硫利达嗪联合氯雷他定抑制胃肠道肿瘤作用的研究

摘要
图/表
参考文献(20)
相关文章 (4)

全文: PDF (0 KB) HTML (59 KB)
输出: BibTeX | EndNote (RIS)

摘要目的初步探讨神经系统药物对胃肠道肿瘤的作用。方法选取硫利达嗪、氯雷他定、东莨菪碱、多巴胺、乙酰胆碱、舒乐安定6种经典的神经系统药物，利用CCK-8法，从0.01、0.1、1、10、100 μmol/L不同浓度梯度分别检测其对胃肠道肿瘤体外的活性。并以小鼠脾脏淋巴细胞为模型，研究神经系统药物在体外对免疫细胞的安全性。结果6种经典的神经系统药物中，100 μmol/L东莨菪碱、100 μmol/L氯雷他定和10 μmol/L硫利达嗪对人结肠癌和人胃癌细胞产生毒性（均P<0.05），并且以硫利达嗪和氯雷他定的组合最为有效。6种神经系统药物仅对肿瘤细胞起到杀伤的作用，而对正常小鼠的脾淋巴细胞无毒性。10 μmol/L硫利达嗪联合25 μmol/L氯雷他定体外抑制鼠源结肠癌细胞和鼠源胃癌细胞。结论硫利达嗪联合氯雷他定在体外可以有效地提高抗胃肠道肿瘤作用，为进一步联合治疗提供新策略。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张金梅
	康文全
	靳广毅
	陈婷婷

关键词 ：硫利达嗪, 氯雷他定, 神经系统药物, 胃肠道肿瘤, 联合治疗

Abstract：ObjectiveTo discuss the preliminary effect of nervous system drugs on gastrointestinal tumors.MethodsThioridazine,Loratadine,Scopolamine,Dopamine,Acetylcholine and Estazolamum(0.01,0.1,1,10,100 μmol/L),six classical nervous system drugs were selected to detect the activities of gastrointestinal tumor in vitro by using CCK-8 assay.The spleen cells of mice were also used as the model to study the safety of the nervous system drugs in vitro.ResultsAmong six classical nervous system drugs,cell growth on human colon and gastric cancer clells were suppressed by 100 μmol/L scopolamine,100 μmol/L Loratadine and 10 μmol/L Thioridazine (P<0.05),especially the combination of Thioridazine and Loratadine.Six drugs only played roles in killing tumors cells,while the spleen lymphocytes of normal mice were non-toxic.The growth of mouse gastrointestinal carcinoma cells in vitro were inhibited by 10 μmol/L thioridazine and 25 μmol/L Loratadine.ConclusionThioridazine combined with Loratadine is proved to enhance anti-gastrointestinal tumor effects in vitro,and provides a new strategy for forward combination treatment.

Key words： Thioridazine Loratadine Nervous system drugs Gastrointestinal tumor Combination therapy

基金资助:广东省深圳市南山区科技创新局重点资助项目（南科研卫2015003）

通讯作者: 陈婷婷（1985-），女，山东人，博士，助理研究员，研究方向：免疫炎症

作者简介: 张金梅（1978-），女，湖北随州人，硕士，主治医师，研究方向：消化系统肿瘤

引用本文:

张金梅;康文全;靳广毅;陈婷婷. 硫利达嗪联合氯雷他定抑制胃肠道肿瘤作用的研究[J]. 中国当代医药, 2017, 24(12): 4-8.
ZHANG Jin-mei;KANG Wen-quan;JIN Guang-yi;CHEN Ting-ting. Study of the effect of Thioridazine combined with Loratadine on the gastrointestinal tumor suppressor. 中国当代医药, 2017, 24(12): 4-8.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I12/4

[1]	王美平，巩志荣，张翮，等.肿瘤治疗新策略：联合药物疗法同时杀伤肿瘤细胞和肿瘤干细胞[J].中国新药杂志，2015，24（10）：1128-1133.
[2]	Masters GA，Krilov L，Bailey HH，et al.Clinical Cancer Advances 2015：annual report on progress against cancer from the American Society of Clinical Oncology[M].J Clin Oncol，2015.
[3]	Eisenhofer G，Aneman A，Friberg P，et al.Substantial production of dopamine in the human gastrointestinal tract[J].J Clin Endocrinol Metab，1997，82（11）：3864-3871.
[4]	Beaulieu JM，Gainetdinoy RR.The physiology，signaling，and pharmacology of dopamine receptos[J].Pharmacol Rev，2011，63（1）：182-217.
[5]	Chakroborty D，Sarkar C，Mitra Rb，et al.Depleted dopamine in gastric cancer tissues：dopamine treatment retards growth ofgastriccancerbyinhibitingangiogenesis[J].ClinCancerRes，2004，10（13）：4349-4356.
[6]	Basu S，Nagy JA，Pal S，et al.The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascularendothelial growth factor[J].Nat Med，2001，7（5）：569-574.
[7]	董铁英，宣奇佳，刘航，等.多巴胺D2受体在肿瘤治疗中的研究进展[J].现代生物医学进展，2015，15（16）：3165-3167.
[8]	Basu S，Sarkar C，Chakroborty D，et al.Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis[J].Cancer Res，2004，64（16）：5551-5555.
[9]	Sarker C，Chakroborty D，Chowdhury UR，et al.Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models[J].Clin Cancer Res，2008，14（8）：2502-2510.
[10]	Saha B，Mondal AC，Basu S，et al.Circulating dopamine level，in lung carcinoma patients，inhibits proliferation and cytotoxicity of CD4+and CD8+T cells by D1 dopamine receptors：an in vitro analysis[J].Int Immunopharmacol，2001，1（7）：1363-1374.
[11]	Nakagome K，Imamura M，Okada H，et al.Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation[J].J Immunol，2011，15，186（10）：5975-5982.
[12]	Asada M，Ebihara S，Numachi Y，et al.Reduced tumor growth in a mouse model of schizophrenia，lacking the dopamine transporter[J].Int J Cancer，2008，123（3）：511-518.
[13]	Sachlos E，Risueno RM，Laronde S，et al.Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells[J].Cell，2012，149（6）：1284-1297.
[14]	Dobbeling U，Waeckerle-men Y，Zabel F，et al.The antihistamines clemastine and desLoratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines[J].Exp Dermatol，2013，22（2）：119-124.
[15]	Hadzijusufovic E，Peter B，Gleixner KV，et al.H1-receptor antagonists terfenadine and Loratadine inhibit spontaneous growth of neoplastic mast cells[J].Exp Hematol，2010，38（10）：896-907.
[16]	Soule BP，Simone NL，Degraff WG，et al.Loratadine dysregulates cell cycle progression and enhances the effect of radiation in human tumor cell lines[J].Radiat Oncol，2010，3（5）：8.
[17]	Medjber K，Freidja ML，Grelet S，et al.Role of nicotinic acetylcholine receptors in cell proliferation and tumour invasion in broncho-pulmonary carcinomas[J].Lung Cancer，2015，87（3）：258-264.
[18]	Park MS，Dong SM，Kim BR，et al.Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/ PI3K/mTOR pathway in ovarian cancer xenografts[J].Oncotarget，2014，5（13）：4929.
[19]	Spengler G，Csonka A，Molnar J，et al.The anticancer activity of the old Neuroleptic Phenothiazine-type drug Thioridazine[J].Anticancer Res，2016，36（11）：5701-5706.
[20]	Chen JS，Lin SY，Tso WL，et al.Checkpoint kinase 1-mediated phosphorylation of Cdc25C and bad proteins are involved in antitumor effects of Loratadine-induced G2/M phase cell-cycle arrest and apoptosis[J].Mol Carcinog，2006，45（7）：461-478.